Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting.

person Maud Marques Exactis Innovation, Montreal, QC, Canada info_outline Maud Marques, Karen Gambaro, Mark Basik, Fred Saad, Saima Noor Hassan, Dominique Boudreau, Francois Vincent, Eve St-Hilaire, Helen Mackay, Mahmoud Abdelsalam, Stephanie Guillemette, Ricardo Leite, Marc-Andre Caron, Chandni Patel, Gerald Batist

Authors person Maud Marques Exactis Innovation, Montreal, QC, Canada info_outline Maud Marques, Karen Gambaro, Mark Basik, Fred Saad, Saima Noor Hassan, Dominique Boudreau, Francois Vincent, Eve St-Hilaire, Helen Mackay, Mahmoud Abdelsalam, Stephanie Guillemette, Ricardo Leite, Marc-Andre Caron, Chandni Patel, Gerald Batist Organizations Exactis Innovation, Montreal, QC, Canada, Segal Cancer Center, Montreal, QC, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada, Hopital St-Sacrement, Quebec City, QC, Canada, Centre Intégré Universitaire de Sante et Services Sociaux, Mauricie-Centre-du Quebec, Trois-Rivières, QC, Canada, Center of Oncology Léon Richard, Moncton, NB, Canada, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, The Moncton City Hospital, Moncton, NB, Canada, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, Novartis Canada, Toronto, ON, Canada, Novartis Corporation, Montreal, QC, Canada, Segal Cancer Centre, Jewish General Hospital/McGill, Montreal, QC, Canada Abstract Disclosures Research Funding Novartis Pharmaceuticals Canada Inc Background: Breast cancer is the most prevalent cancer and second leading cause of cancer-related mortality among Canadian women. Most of cases belong to the HR+/HER2- subtype, representing approximately two-thirds of all instances. Treatment for this subtype encompasses a multifaceted approach with a curative intent. This real-world evidence study aims to comprehensively analyze the clinical outcomes of Canadian patients diagnosed with early-stage HR+/HER2- breast cancer, focusing on recurrence rates after initiation of adjuvant endocrine therapy to identify opportunities for enhancing patient care. Methods: This is a retrospective, longitudinal cohort study involving 541 patients enrolled in the pan-Canadian cancer patient registry PMT (Personalize My Treatment), with newly diagnosed or recurrent stage II or III HR+/HER2- breast cancer between January 1 st , 1996, and May 31st, 2022. We evaluated disease recurrence rates, time to recurrence, and overall survival (OS). Furthermore, the study explored duration of endocrine therapy (ET) in the adjuvant setting. Results: 409 patients received adjuvant ET representing 75.6% of the total cohort, emphasizing the role of ET as standard of care for adjuvant treatment in this patient population. The median duration of adjuvant ET was 4.5 years. In the overall adjuvant patient population, recurrence rates progressively increased over time from 13.2% after 2 years, 21.4% after 3 years, 30.3% after 5 years, and peaking at 58.4% after 10 years. Median time to recurrence for the overall patient population on ET was 7.76 years. OS rate for patients on ET was 94.6% at 5 years and 78.3% at 10 years. Conclusions: This study marks a pioneering real-world analysis utilizing pan-Canadian EHR data, demonstrating increasing recurrence rates over time in HR+/HER2- early breast cancer. It highlights the high unmet need in stage II and stage III breast cancer, with 1 patient out of 3 recurring after 5 years, and more than half recurring after 10 years despites adjuvant treatment with ET alone. This indicates the need for more efficacious and tolerable treatment options to reduce short- and long-term recurrence and to prolong survival, not only in the higher risk patient population, but in the overall HR+/HER2- breast cancer patients at increased risk of recurrence.